Europe Gas Steadies After Three-Day Fall as Traders Watch Demand
Benchmark futures hovered around €33 a megawatt-hour on Tuesday after hitting a three-week low in the previous session.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
$515M Bet on Musk, AI, and Space: Glade Brook Goes All-In While Others Retreat
Glade Brook Capital Partners just pulled in $515 million for its fourth fund and it's placing its bets on the edge of what's next: AI, space, defense, and fintech. The firm, which already holds stakes in SpaceX, Stripe, and Elon Musk's Neuralink, plans to double down on late-stage tech startups navigating some of the most volatile capital markets in recent memory. Founder Paul Hudson didn't sugarcoat the conditions, calling it the most challenging fundraising environment he's seen in his career even as the fund ended up oversubscribed. Despite the headwinds, Glade Brook is leaning into momentum. It's already backing Musk's xAI and Artisan AI, signaling a clear tilt toward artificial intelligence. That comes on top of a portfolio that includes ramping fintech player Ramp and previously backed giants like Uber (NYSE:UBER) and Airbnb (NASDAQ:ABNB). And in a move that tracks closely with broader market appetite, the firm is betting that innovation in complex, capital-intensive sectors like AI and defense could offer asymmetric upside if timed right. Tesla (NASDAQ:TSLA) remains part of the broader Musk-aligned orbit Glade Brook is exposed to, adding even more edge to its late-stage tech focus. Their 2021 fund a $430 million vehicle reportedly ranks in the top 5% of its vintage, according to private Cambridge Associates data. While past performance doesn't guarantee future returns, it does suggest Glade Brook knows how to play late-stage cycles. In a market where many VCs are stuck in wait-and-see mode, Glade Brook appears to be playing offense betting that when the next wave breaks, it'll be the firms already in position that ride it the farthest. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Increasing Fundings and Investments, Advanced Liquid Biopsy Technologies and Early Detection Methods Fuelling Growth
The global cancer diagnostics market, valued at USD 23.84 billion in 2024, is forecasted to grow at an 11.5% CAGR, reaching USD 70.80 billion by 2034. Key drivers include rising cancer cases, early detection initiatives, and technological advances like AI and liquid biopsies. The robust market includes leaders like Roche, Thermo Fisher, and expanding regions such as North America. Cancer Diagnostics Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The "Cancer Diagnostics Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)" report has been added to global cancer diagnostics market was valued at USD 23.84 Billion in 2024, driven by the rising prevalence of cancer and increasing awareness and early detection initiatives across the globe. The market is anticipated to grow at a CAGR of 11.50% during the forecast period of 2025-2034, with the values likely to reach USD 70.80 Billion by 2034 . Cancer diagnostics involves identifying cancer early to improve treatment outcomes. It typically starts with a clinical evaluation, including physical exams and medical history reviews. Diagnostic tests like imaging (X-rays, CT scans, MRIs, PET scans) detect abnormalities, while blood tests identify cancer markers. Biopsies, where tissue samples are examined under a microscope, confirm malignancy and provide detailed information about the tumour. Advanced methods, such as molecular testing, identify genetic mutations to guide personalised treatments. Screening programmes, like mammograms and colonoscopies, help detect cancer in its early stages. Accurate diagnostics are essential for effective treatment planning and monitoring of disease Diagnostics Market Growth Drivers Rising Merger and Acquisition Activities to Accelerate Market GrowthIncreasing demand for specialised cancer diagnostics and expanding healthcare access in emerging regions are major drivers of growth in the market. For instance, in December 2024, Metropolis Healthcare Limited announced its acquisition of Core Diagnostics, based in Delhi NCR, for USD 29.62 million. This acquisition aims to strengthen Metropolis' cancer testing services and enhance its footprint across Northern and Eastern India. With Core Diagnostics' extensive oncology portfolio and its established network of 200 cities, this move will drive market expansion and enhance diagnostic capabilities. The deal is set to propel Metropolis into a leading position, stimulating market growth in the forecast period by offering advanced cancer diagnostics to a wider Fundings and Investments to Meet Rising Cancer Diagnostics Market DemandGrowing investments in innovative cancer therapies and advancements in radiotherapy are key drivers for the expanding market. For instance, in November 2024, ARC Innovation, part of Sheba Medical Center, secured USD 5.1 million in funding for Starget Pharma, a startup developing targeted radioligand therapies for precise cancer diagnosis and treatment. With funding from the Cancer Focus fund, supported by MD Anderson Cancer Center, Starget Pharma plans to conduct clinical trials on cancers such as sarcomas and melanoma. This breakthrough in cancer diagnostics and treatment will likely enhance the efficacy of therapies and offer new diagnostic tools, positioning this technology to significantly impact the global market in the forecast Diagnostics Market TrendsAdvanced Liquid Biopsy Technologies and Early Detection Methods Fuelling Market GrowthThe market is experiencing the rapid adoption of liquid biopsy technologies, which enable the detection of genetic mutations and biomarkers through blood samples. These non-invasive diagnostic tools are revolutionizing cancer detection by offering early diagnosis and real-time monitoring of treatment response. Liquid biopsy's increased accuracy and reduced patient discomfort are contributing to its growing popularity, particularly in precision oncology. As healthcare systems focus on improving early cancer detection, this technology's market demand is expected to rise significantly. Furthermore, advancements in molecular biology and bioinformatics will further boost its integration into clinical practice, expanding its market of Advanced Technologies to Impact the Cancer Diagnostics Market Value PositivelyArtificial intelligence (AI) and machine learning (ML) are playing a pivotal role in transforming the global cancer diagnostics market. AI-powered diagnostic tools enhance the accuracy of medical imaging, enabling early-stage cancer identification through pattern recognition and predictive analytics. These technologies not only improve diagnostic precision but also streamline workflow efficiencies, reduce human errors, and enhance treatment outcomes. With substantial investments being poured into AI in healthcare, the demand for AI-driven diagnostic solutions is growing. As the technology continues to evolve, its integration into cancer diagnostics will significantly increase market growth, driving future market value and development in the healthcare Partnerships Poised to Drive Cancer Diagnostics Market GrowthThe growing demand for precise and personalised cancer diagnostics is driving strategic collaborations in the field. For instance, in August 2024, Hitachi High-Tech Corporation and Gencurix, Inc. formed a partnership to develop cancer molecular diagnostics. By combining Hitachi's expertise in in vitro diagnostics and digital technologies with Gencurix's proficiency in biomarker discovery, the two companies aim to create advanced testing services. After a successful feasibility study, both companies are now set to commercialise these services in Japan. This collaboration will likely enhance the availability of molecular testing for cancer diagnosis, accelerating the growth of the global cancer diagnostics market by offering cutting-edge, more accurate diagnostic of Next-Generation Sequencing Technology to Increase Cancer Diagnostics Market SizeNext-generation sequencing (NGS) is a breakthrough technology that is rapidly transforming the global cancer diagnostics market. NGS offers high-throughput genomic analysis, enabling comprehensive testing of cancerous tissues to identify genetic mutations and potential therapeutic targets. This technology facilitates early detection of cancer, personalized treatment planning, and monitoring of therapeutic efficacy, contributing to better patient outcomes. The increasing availability of cost-effective NGS platforms and advancements in bioinformatics are driving its integration into clinical oncology practices. As a result, the NGS segment within the cancer diagnostics market is expected to experience substantial growth, adding significant value to the overall market. Key Questions Answered in the Cancer Diagnostics Market What was the global cancer diagnostics market value in 2024? What is the cancer diagnostics market forecast outlook for 2025-2034? What is market segmentation based on technology? How is the market segmented based on application? How is the market segmented based on clinical positioning? What are the major factors aiding the global cancer diagnostics market demand? How has the market performed so far and how is it anticipated to perform in the coming years? What are the market's major drivers, opportunities, and restraints? What are the major cancer diagnostics market trends? Which technology will lead the market segment? Which application will lead the market segment? Which clinical positioning will lead the market segment? Who are the key players involved in the cancer diagnostics market? What is the patent landscape of the market? What are the current unmet needs and challenges in the market? How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics? Key Attributes: Report Attribute Details No. of Pages 400 Forecast Period 2025 - 2034 Estimated Market Value (USD) in 2025 $23.84 Billion Forecasted Market Value (USD) by 2034 $70.8 Billion Compound Annual Growth Rate 11.5% Regions Covered Global Supplier Landscape Agilent Technologies, Inc. F. Hoffmann-La Roche AG Thermo Fisher Scientific, Inc. Becton, Dickinson and Company Danaher Corporation GE Healthcare Abbott Siemens Healthineers Bio-Rad Laboratories, Inc. Illumina, Inc. PerkinElmer Inc. QIAGEN Hologic, Inc. Myriad Genetics, Inc. Sysmex Corporation NeoGenomics Laboratories, Inc. Foundation Medicine Grail Guardant Tempus Delfi Diagnotics Exact Sciences Corporation Cancer Diagnostics Market SegmentationMarket Breakup by Technology Blood-based Diagnostics In Vitro Diagnostics Immunoassays Histopathology Others Molecular Diagnostics cfDNA Testing DNA Methylation Analysis Gene Sequencing Polymerase Chain Reaction (PCR) In Situ Hybridization Isothermal Nucleic Acid Amplification Technology (INAAT) Microarrays Spectrometry Others Non-blood-based Diagnostics Imaging CT MRI PET Others Biopsy Comparative Analysis Solid Liquid Others Others Market Breakup by Indication Breast Cancer Lung Cancer Colorectal Cancer Prostate Cancer Cervical Cancer Blood Cancers (Leukemia and Lymphoma) Skin Cancer (Melanoma) Others Market Breakup by Clinical Positioning Screening Early Detection Treatment Guidance Treatment Response Assessment Market Breakup by Region North America Europe Asia Pacific Latin America Middle East and Africa For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Cancer Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
China's yuan undervaluation fuels euro zone trade deficit, German study shows
By Reinhard Becker and Sarah Marsh BERLIN (Reuters) -European companies are facing increasing pressure due to China's alleged currency manipulation to keep its yuan weak, a study by the German Economic Institute showed, as EU leaders prepared for a summit in Beijing aimed at navigating trade disputes. The yuan-euro exchange rate has remained stable in recent years despite significant shifts in cost relations between Europe and China, suggesting likely currency manipulation by the central bank, said Juergen Matthes, author of the study by the Institute (IW), which was seen by Reuters. Extremely low prices mean more European companies are sourcing intermediate goods from China, contributing to deindustrialisation on the continent, he said, urging the EU to take action. "The artificially low costs in China, driven by yuan undervaluation, are simply too attractive," Matthes said. Those companies that did not source their intermediate goods from China would lose market share to rivals who "fully exploit China's price advantages." The Chinese central bank did not immediately respond to a request for comment. EU leaders arrive in Beijing on Thursday for a top-level summit with China as both sides seek to navigate trade disputes amid broader global trade uncertainties. In response to allegations of currency manipulation, China has in the past said it was committed to implementing a managed floating exchange rate regime, based on market supply and demand. UNDER PRESSURE The study comes as European companies are under pressure from a surge in Chinese exports diverted from the United States and an appreciation of the euro against the dollar due to U.S. President Donald Trump's trade policies, economists say. Producer prices in Germany and the euro zone have surged since 2020 due to supply chain disruptions and the energy crisis, whereas prices in China have hardly increased. Yet, the exchange rate has barely moved, leading to a real appreciation of the euro against the yuan of over 40% between early 2020 and spring 2025, and deepening the euro zone trade deficit with China, the study shows. Normally, higher import purchases from the euro zone would boost the yuan as it drives up demand for the currency, but that has not been the case, said Matthes. President Trump labeled China a currency manipulator during his first term. The Treasury Department then dropped the designation in January 2020 as Chinese officials arrived in Washington to sign a trade deal with the U.S. Last month, the U.S. simply issued a stern warning to China, saying it stood out among key trading partners "in its lack of transparency around its exchange rate policies and practices." China said it upheld "multilateralism and respects multilateral consensus," was committed to keeping the renminbi exchange rate stable, and would not "engage in competitive currency devaluation." Matthes, however, said the Chinese central bank's behavior was "highly non-transparent." When adjusting the yuan exchange rate, which is only allowed to fluctuate within a narrow band, the dollar relationship plays a central role, as does a currency basket, he said. "But how this is done, exactly, no one outside China knows,' he said, and the euro is "collateral damage."
